Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06334640
Recruiting Observational

Sleeping Quality and Chronic Ocular Diseases

NCT06334640 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Auxologico Italiano
Phase
Observational
Started
2023-10-17
Last updated
2025-05-04

Condition(s) studied

Sleep Disorder

Investigational drug(s) / intervention(s)

Three questionaires

Three questionaires: Berlin, Pittsburgh and Epworth tests administered during study visit

Study summary

To assess the impact of sleep quality on chronic eyes diseases

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with macular degeneration or glaucoma or * Healthy volunteers Exclusion Criteria: \- Patients with other ocular disorders

Primary outcome measure(s)

  • Proportion of sleep disorders in patients and healthy volunteers — At enrollment
    To analyze the prevalence of sleep disorders in subjects affected by glaucoma and macular degeneration and in healthy volunteers as assessed by Berlin, Pittsburgh and Epworth questionnaires

Trial sites (1)

FacilityCityRegionStatus
Istituto Auxologico Italiano IRCCS Milan Italy Recruiting

More Istituto Auxologico Italiano trials in Italy

Implantable Loop Recorder and Cardioneuroblation Starting soon
Vesiculogenesis in Children With GH Deficiency (VESCIGHTP) Active, not recruiting
Exploring the Full Body Representation in Anorexia Nervosa and Bulimia Nervosa Recruiting
Impact of WBC on Patients With Metabolic or Neurological Diseases or Fibromyalgia (WBC-MeNeFi) Recruiting
The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study Recruiting

Other trials for the same condition

Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06334640 on ClinicalTrials.gov ↗ ← All trials in Italy